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HumanChronic oral exposure to hexavalent chromium (Cr-VI) in drinkingwater has been shown to induce tumors in the
mouse gastrointestinal (GI) tract and rat oral cavity. The same is not true for trivalent chromium (Cr-III). Thus re-
duction of Cr-VI to Cr-III in gastric juices is considered a protectivemechanism, and it has been suggested that the
difference between the rate of reduction among mice, rats, and humans could explain or predict differences in
sensitivity to Cr-VI. We evaluated previously published models of gastric reduction and believe that they do
not fully describe the data on reduction as a function of Cr-VI concentration, time, and (in humans) pH. The pre-
vious models are parsimonious in assuming only a single reducing agent in rodents and describing pH-
dependence using a simple function. We present a revised model that assumes three pools of reducing agents
in rats and mice with pH-dependence based on known speciation chemistry. While the revised model uses
more ﬁtted parameters than the original model, they are adequately identiﬁable given the available data, and
the ﬁt of the revised model to the full range of data is shown to be signiﬁcantly improved. Hence the revised
model should provide better predictions of Cr-VI reduction when integrated into a corresponding PBPK model.
Published by Elsevier Inc.Introduction
Oral exposure to hexavalent chromium (Cr-VI) has been shown to
induce tumors in the mouse gastrointestinal (GI) tract and rat oral cav-
ity, while trivalent chromium (Cr-III) does not exhibit this carcinogenic
potential (Stout et al., 2009). This difference in response is attributed in
part to the much greater absorption (bioavailability) of Cr-VI vs. Cr-III
(Febel et al., 2001; Kerger et al., 1996). As a result, the reduction reaction
of Cr-VI to Cr-III in the gastrointestinal tract is considered to be a major
pathway for detoxiﬁcation in humans and rodents (De Flora et al.,
2008). While small quantities of Cr-VI can be reduced rapidly in GI
juices, larger amounts are reducedmore slowly, or deplete the available
reducing agents (Proctor et al., 2012). Reduction rates are also pH-
dependent, becoming slower as pH increases (Kirman et al., 2013).
In this article we describe a revision of a mathematical model of Cr-
VI reduction in gastric juices ex vivo. By itself such a model can lend
some understanding of Cr-VI dosimetry, but to be quantitatively useful
it must be integrated into PBPK models of kinetics in the GI and whole
body, as depicted in Fig. 1. The kinetic equations and parameters from
the ex vivo model are used to predict Cr-VI reduction rates in a GI
tract (sub)model, which in this illustration is comprised of three com-
partments: stomach, duodenum, and jejunum. Ingestion of Cr-VI is
described as an inﬂux into the stomach compartment, where it canRTP, NC 27711, United States.
r).either be reduced or transferred to the next GI compartment.
Compartment- and species-dependent GI characteristics which effect
the rate of reduction include gastric emptying rates, lumen volumes,
the mass of reducing agents (electron donors which reduce Cr-VI),
and lumen pH. The GI-tract (or whole-body) model would also include
the rate of reducing agent replenishment through ingestion and secre-
tion into the lumen in gastric juices.
Reduction of Cr-VI, which occurs largely in the stomach, competes
with the transfer of Cr-VI to the small intestinewhere it is absorbed. Re-
duction and gastric emptying occur simultaneously and the fraction of
Cr-VI that is transferred and hence available for absorption depends
on the relative rate of transfer vs. reduction. Thus the rate of absorption
and hence cancer risk in humans as compared to rodents will be im-
pacted by species differences in pH and the amount of reducing agents
present. Accurate prediction of human cancer risks is likely to depend
on accurately modeling the dependence of Cr-VI's reduction rate on
these factors. Given the complexities and time-dependencies of Cr-VI
in the whole body and the critical role of Cr-VI reduction in gastric
juices, it makes sense to ﬁrst model reduction in the isolated, ex vivo
setting.
Proctor et al. (2012) developed a simple model of Cr-VI reduction ki-
netics for the rat and mouse at a single pH using kinetics measured
ex vivo, which was then integrated into the PBPK model of Kirman et al.
(2012). The PBPK model also incorporated a pH-dependence term
based on experiments with human gastric juices ex vivo. Kirman et al.
(2013) provide details of those human ex vivo kinetic data and describe
their incorporation into a human PBPK model. These reduction models
Fig. 1. Schematic of integration of ex vivo reduction kinetics into in vivo gastric and whole-body PBPK models.
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lated ex vivo experiments the total amount of reducing agent is limited to
the total amount present in the gastric juices and is eliminated stoichio-
metrically (one-to-one)with Cr-VI. Themodel does not consider the spe-
ciation of Cr-VI, which depends on both pH and total Cr-VI concentration
(Brito et al., 1997). While Proctor et al. (2012) mention a number of re-
ducing agents known to be present in gastric juices (ascorbate, glutathi-
one, NADH, sulfhydryls), they used a simpliﬁed lumped-parameter
model with a goal of parsimony. Close examination of their results, how-
ever, shows that the model adequately ﬁts low concentration reduction
data, but under-predicts the reduction observed at higher concentrations.
Like the previous model of Proctor et al. (2012) we assume that
the stomach juices contain one or more reducing agents – electron
donors – which react with Cr-VI chemical species to reduce Cr to
Cr-III. It is clear from the data that one or more cofactors are available
in limited supply, as small amounts of Cr-VI are very rapidly reduced,
but the reduction rate diminishes with time, and this exhaustion of
the cofactor(s) occurs more quickly at high initial Cr-VI concentra-
tions. While ascorbate, glutathione, NADH, sulfhydryls can all serve
as reducing agents, the speciﬁc concentrations of each of these in
the stomach juices used to measure Cr-VI reduction (by Proctor
et al., 2012, and Kirman et al., 2013) and their individual reaction
rates with Cr-VI (species) are not known. Hence, like Proctor et al.
(2012), we use here the generic term “reducing agents”, and that as-
pect of the model is phenomenological.
Webelieve that there are several shortcomings in the previousmodels
which can be improved upon. The pH-dependence was evaluated by
Kirman et al. (2013) by separately ﬁtting the reduction data at each pH
(and each Cr-VI concentration and dilution of gastric juices) using the
same reductionmodel, thereby obtaining a different value of the effective
binary rate constant, keff, for each experimental condition. When the au-
thors plotted the binary constants obtained this way vs. pH, keff was ob-
served to roughly vary as exp(−pH); i.e., keff was assumed to equal
k0g ∙ exp(−pH), where k0g is a pH-independent rate constant. However
this is only an empirical observation, since pH is deﬁned as the base-10
logarithm of 1/[H+] and a direct relationship between reduction rate
and proton concentration is not expected. Further, the keff obtained by
ﬁtting the reduction data at pH = 1 is 3-fold lower than that obtained
using the pH = 1.3 data, a difference not consistent with the assumed
pH-dependence, which predicts a 35% higher value at pH= 1 vs. 1.3. At
pH = 4, two values of keff were obtained that differed by a factor of 5,
from ﬁtting keff to two data sets obtained at different dilutions of gastric
juice and initial Cr-VI concentration, indicating a dependence on other ex-
perimental variables (dilution of gastric juices or Cr-VI concentration)
that the model does not capture.In our revised model, we attempt to describe the pH-dependence
based on the observed pH-dependent speciation of Cr-VI, assuming
that differences in the reduction rate occur due to the shift in relative
abundance of speciﬁc forms of Cr-VI. According to Brito et al. (1997),
chromate(VI) in aqueous solution appears primarily as one of three
forms at pH N 3: chromate (CrO42−), hydrogen chromate (HCrO4−), and
dichromate (Cr2O72−). At pH b 3, hydrogen dichromate (HCr2O7−) and
chromic acid (H2CrO4) also become signiﬁcant. In particular, the con-
centration fractions of HCrO4− and Cr2O72− decline signiﬁcantly for
pH N 5, converting to CrO42−. So, in particular, we assumed that either
HCrO4− or Cr2O72− was the predominant substrate for reduction since
they are predominant at low pH; i.e., that the reduction rate of Cr-VI de-
creases with increasing pH because HCrO4− or Cr2O72− is the formwhich
participates in the reduction reaction, and as pH increases the amount
of Cr-VI present in these forms decreases. By using this mechanism-
based model of pH-dependence, it may be possible to more accurately
describe the observed variation in reduction rates with pH.
Since the concentration-dependence of Cr-VI reduction appeared to
be not completely captured by Proctor et al. (2012), additional pools of
reducing agents were also considered, with the number of pools evalu-
ated separately for mice, rats, and humans, based on themodel's ability
to ﬁt the data for that species.
Material and methods
The experimental design and methodology are described in Proctor
et al. (2012) and Kirman et al. (2013). The source data were graciously
made available by the study authors. Modeling and analysis for this cur-
rent work were performed using acslX software (version 3.0.2.1, Aegis
Technologies, Huntsville, AL). The .csl ﬁle is included as supplementary
material.
Original model. As stated in the Introduction, the reduction model used
by Proctor et al. (2012) and Kirman et al. (2013) assumed a single re-
ducing agent (electron donor) pool, with the agent participating in a
binary reaction with Cr-VI:
hence :
reduction rate ¼ keff R½   Cr‐VI½ ;
d Cr VI½ 
dt
¼ d R½ 
dt
¼ keff R½   Cr‐VI½ ;
where [Cr-VI] is the total concentration of Cr-VI present, in all chemical
forms and [R] is the concentration of the reducing agent. R was assumed
to have an initial concentration, [R]initial, whichwas adjusted toﬁt the ex-
perimental data along with the binary rate constant, keff. Proctor et al.
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using “K” for keff, and obtained keff = 0.004983 L ∙mg−1 ∙min−1 (report-
ed as 0.3 L ∙mg−1 ∙ h−1) and [R]initial = 15.74 mg ∙ L−1 for the rat and
keff = 0.003295 L ∙mg−1 ∙ min−1 (reported as 0.2 L ∙mg−1 ∙ h−1) and
[R]initial = 16.64 mg ∙ L−1 for the mouse (exact values from personal
communication). Since the experiments of Proctor et al. (2012) were
conducted with rodent gastric juices diluted 10-fold, and we chose to
build the dilution adjustment explicitly into our assumptions, these
values of [R]initial were converted to un-diluted values, R0 = 157.4 and
166.4 mg ∙ L−1 for the rat and mouse, respectively.
Kirman et al. (2013) conducted experiments at multiple dilutions
and pH values and used the symbol “Kred”. To estimate the reduction
rate constant for each pH/dilution combination, the corresponding re-
duction time-course was ﬁtted with
keff or Kredð Þ ¼ kgastrict  dil
where kgastric was assumed to be the effective constant for undiluted
gastric juices and dil is the fold dilution. The initial concentration of re-
ducing agent was set as [R]initial = R0/dil, where R0 is the initial concen-
tration in undiluted gastric juices. After obtaining values of kgastric for
each dilution and pH value, these values were plotted vs. pH and a func-
tion was ﬁt to the resulting values, as:
kgastrict ¼ k0g  exp −pHð Þ:
Hence the reduction model of Kirman et al. (2013) as used in ﬁtting
the ex vivo reduction data can be summarized as:
keff ¼ k0g  exp −pHð Þ  dil and R0=dil;
given the reduction rate and differential equations listed above.
Kirman et al. (2013) obtained k0g = 44.5 L ∙ mg−1 ∙ h−1 =
0.742 L ∙ mg−1 ∙ min−1 for humans. Separate values of R0 were ﬁt
to each data set they examined; the mean of these is 7.27 mg ∙ L−1
(exact value based on results provided by Dr. Kirman and
colleagues).
Comparison of original and revised models. Our alternate model, de-
scribed below, is compared to the results of Kirman et al. (2013) by
showing model ﬁts to individual experiments. For our model, we
performed a global optimization over all data sets simultaneously,
with the dependence on pH and dilution built into the model. There-
fore, our data-set-speciﬁc rate constants are not distinct from the
overall regression but are deﬁned by it. Since the model form used
by Kirman et al. (2013) for the in vivo PBPK model is deﬁned by
keff = k0g ∙ exp(−pH) ∙ dil (with dil = 1, corresponding to the re-
gression line shown in Fig. 2C of their publication), an appropriate
test and comparison of their model is therefore to use the keff deﬁned
by that regression line. This was preferred to using the data-set-
speciﬁc rate constants indicated as points in the published ﬁgure
panel.
pH-dependence. As discussed in the Introduction, we sought to describe
the pH-dependence of Cr-VI reduction mechanistically, based on the
corresponding pH-dependent chemical equilibria among Cr-VI forms.
Chromate speciation equilibria can be described by four reversible reac-
tions (Brito et al., 1997):
CrO2−4 þ Hþ →← HCrO
−
4 ; K11 ¼
HCrO−4½ 
CrO2−4
 
Hþ½  ð1Þ
2HCrO−4
→
← Cr2O
2−
7 þ H2O; K22 ¼
Cr2O
2−
7
h i
HCrO−4
 2 ð2ÞHCrO−4 þHþ →← H2CrO4; K21 ¼
H2CrO4½ 
HCrO−4
 
Hþ½  ð3ÞCr2O
2−
7 þHþ →← HCr2O
−
7 ; K32 ¼
HCr2O
−
7½ 
Cr2O
2−
7
 
Hþ½  ð4Þ
While wewould prefer to use separate forward and reverse reaction
rates for each of these, separate rate constants were not available.
Therefore we chose to assume that these reactions are relatively fast
compared to reduction, hence can be treated as at equilibrium.
Since only the total amount of Cr-VI is known (either as the initial
amount added or calculated as what remains after a given degree of re-
duction), the set of equilibrium equations, (1)–(4), must be solved si-
multaneously to determine the concentration of each chromium
species: [CrO42−], [HCrO4−], [Cr2O72−], [H2CrO4], and [HCr2O7−]. Given
the pH (i.e., [H+]) and mass balance for total Cr-VI,
[CrO42−] + [HCrO4−] + [H2CrO4] + 2[Cr2O72−] + 2[HCr2O7−] =
[Cr-VI]Total,
these can be solved algebraically for the individual chemical species
concentrations as a function of [Cr-VI]Total, for example:
CrO2−4
h i
¼
− B þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
B2 þ 4  A  Cr−VI½ Total
q
2  A
where
A ¼ 2  K22  K11  Hþ
h i 2  1 þ K32  Hþ
h i 
;
B ¼ 1 þ K11  Hþ
h i
 1 þ K21  Hþ
h i 
;
HCrO4
−½  ¼ K11  Hþ
h i
 CrO 4−2
h i
;
H2CrO4½  ¼ K21  Hþ
h i
 HCrO4−½ ;
Cr2O7
2−
h i
¼ K22  HCrO4−½ 2;
and
HCr2O7½  ¼ K32  Hþ
h i
 Cr2O72−
h i
¼ K32  K22  Hþ
h i
 HCrO4−½ 2:
Brito et al. (1997) obtained values of K11 = 7.73 × 105 M−1
(pK11 = log10(K11) = 5.888), K22 = 132 M−1 (pK22 = 2.12),
K21 = 13.2 (pK21 = 1.12), and K32 = 15.2 (pK32 = 1.28). For
the concentration range examined by Kirman et al. (2013) with human
gastric juices, [Cr-VI]Total = 0.1–2 mg/L ~ 2 × 10−5–4 × 10−6 M, and
with these equilibrium constants, no more than 1% of the total chromate
is calculated to appear as dichromate. At the higher concentrations used
by Proctor et al. (2012) with mouse and rat gastric juices, a large fraction
appears as dichromate; i.e., 14% of total Cr-VI is in this form for 40 mg/L
total Cr-VI at pH= 4.
We considered the possibility that dichromate is the primary reac-
tive species. However, given the chemistry described above, [Cr2O72−]
varies roughly as the square of [Cr-VI]Total in the concentration range
studied. If the kinetics were modeled as being proportional to
[Cr2O72−], the resulting [Cr-VI]Total vs. time curves differed signiﬁ-
cantly in shape from those obtained when hydrogen chromate was
assumed to be the reactant.Model predictions based on this assumption
were clearly not consistent with the data of Proctor et al. (2012) and
Kirman et al. (2013) (results not shown). When we attempted to ﬁt a
model that allowed both chemical species to react, the rate constant
for the dichromate-dependent term converged to zero. These results
were considered strong evidence that dichromate was not the direct
reactant.
Fig. 2. Ex-vivo model predictions in the rat for different reaction schemes. Data in ﬁrst three panels were used for calibration; data in the lower-right panel were not used for calibration.
Two of the revised rat parameters were ﬁxed to values from the mouse model. An improved model ﬁt at high initial Cr-VI concentrations is achieved by assuming additional reducing
agents are present in the gastric ﬂuid and contents. At low concentration, minimal improvement is achieved (the 2- and 3-reducing agent model results are indistinguishable at
0.1 ppm). Data graciously provided by Summit Toxicology and ToxStrategies, Inc.
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equations above predict that at 1 mg/L total Cr-VI, HCrO4− represents
43% of total Cr-VI at pH = 1, 98.3% at pH = 4, and 7.2% at pH = 7.
Thus, HCrO4− is a species whose relative abundance decreases at higher
pH values (above pH= 4) and this shift in its relative abundance might
explain the pH-dependence of the reduction rate. However, while the
shift in abundance for HCrO4− is qualitatively closer to the empirical
data of Kirman et al. (2013), the difference in HCrO4− abundance be-
tween pH=4 and 7, 13.7-fold, is much less than the change in Cr-VI re-
duction rate observed by Kirman, et al. (2013) (30–160 fold). Further,
between pH = 4 and 1, the equilibrium chemistry predicts a decrease
of 56% in [HCrO4−], but the empirical constants of Kirman et al. (2013)
increased by 2–3 fold.
Therefore we relaxed our initial assumption to include the possibil-
ity that H2CrO4 was equally or more reactive than HCrO4−, but this still
did not provide a good ﬁt to all of the data. The qualitative change in re-
action rate with pH matches the observed data with this relaxed as-
sumption, but the quantitative differences in reaction rate were not
adequately captured. Given that the assumption of a binary reaction
with one more reducing agents was probably also a simpliﬁcation, we
therefore decided to test this model with one of the equilibrium con-
stants being adjusted in order to ﬁt the full data set. Since we had deter-
mined the data to be not consistent with dichromate as a reactant
species (see above), the pH-dependence seemed likely to bemost inﬂu-
enced by the balance between HCrO4− and CrO42−, which depends most
directly on K11. Hence we assumed that varying K11 would provide agood ﬁt to the full data set without varying any of the other parameters.
However, when only K11 was varied and H2CrO4 and HCrO4− were as-
sumed to be equally reactive we found that we could adequately ﬁt
the data from pH = 1 to pH = 4, but that the reaction rate at pH = 7
was now under-predicted. Since [CrO42−] becomes signiﬁcant at
pH N 5, our ﬁnal assumptionwas to allow CrO42− to have a reactivity de-
ﬁned as a fraction, f, of that for H2CrO4 and HCrO4−.
In summary, for each reducing agent pool, Rpool, the rate of reduction
was deﬁned as:
reduction rate ¼ kpool  Rpool
h i
 H2CrO4½  þ HCrO4−½  þ f  CrO42−
h i 
:
Like Kirman et al. (2013), we found that the human reduction
data were adequately described assuming a single pool of reducing
agent, whose concentration in undiluted gastric juice is represented
as R0,1, with the initial concentration in a given experiment set as
R0,1/dil. While we believe it likely that human gastric juices contain
multiple pools of reducing agents, just as appears to be the case in ro-
dents (see below), the range of concentrations evaluated in the
human data set is not sufﬁcient to allow unique identiﬁcation of pa-
rameters for multiple pools. If we attempt to ﬁt a model with two or
three pools to the human data, the parameter estimation does not
properly converge because the fast reducing agent pool is never de-
pleted and its rate masks those for any slower pools. To state this an-
other way, if reduction by human gastric juices occurs via three
Fig. 3. Ex-vivo model predictions in the mouse for different reaction schemes. The original and revised 3-reducing agent models are presented. Data in ﬁrst ﬁve panels were used for cal-
ibration; data in the lower-right panel were not used for calibration. Aswith the rat, the single reducing agentmodel deviatesmost from the data at high initial Cr-VI concentrations. Data
graciously provided by Summit Toxicology and ToxStrategies, Inc.
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cause none of them becomes depleted (i.e., with rate constants kp1,
kp2, and kp3), then the rate of reduction is indistinguishable from
what would occur with a single pool whose rate constant is the
sum of the constants for the three pools; i.e., k1 = kp1 + kp2 + kp3.
Since the parameters are ﬁtted to the empirical reduction data, the
human rate constant, k1, and (undiluted) pool size, R0,1, effectively
incorporate reduction by all human reducing agent pools. Since the
human exposures which will ultimately be evaluated for risk analy-
sis are much lower than those used in the rodent bioassays, webelieve this simpliﬁcation of the human model, to only have one
effective reducing agent pool, will be adequate.
Hence kpool = k1 and Rpool = R1 for the single effective reducing
agent pool for humans, with the initial concentration of reducing
agent in undiluted gastric juice being R0,1. Our human reduction
model is then:
reduction rate ¼ k1  R1½   H2CrO4½  þ HCrO4−½  þ f  CrO42−
h i 
;
R1½ initial ¼ R0:1=dil;
Fig. 4. Ex-vivomodel predictions in the human. The original and revisedmodels are presented. Note changes in initial concentration and time scale between panels. Bothmodels assume a
single reducing agent. At high initial Cr-VI concentration, the original model under-predicts reduction when compared to the revised model. This is most apparent at low pH, where the
reduction rate is the fastest. At low initial Cr-VI concentrations, the single reducing agentmodel tends to over-predict the rate of reduction. Data graciously provided by Summit Toxicology
and ToxStrategies, Inc.
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total Cr-VI concentration as a function of pH, as described above. In com-
parison, the model of Kirman et al. (2013) is:
reduction rate ¼ k0g  dil  R1½   Cr−VI½ Total  exp −pHð Þ
R1½ initial ¼ R0:1=dil:In summary, the two key differences between our model and that of
Kirman et al. (2013) are: 1) we assume the leading rate constant, k1,
does not change with dilution while Kirman et al. (2013) assumed
that their effective rate constant, k0g ∙ dil, increases in direct proportion
with gastric juice dilution; and 2) the pH dependence. The usual as-
sumption for chemical kinetics is that rate constants are not altered by
dilution of the reactants and the dependence on pH we have
Fig. 5. Performance of the revised ex-vivo kinetic model in humans across a wide pH
range. Data graciously provided by Summit Toxicology and ToxStrategies, Inc.
358 P.M. Schlosser, A.F. Sasso / Toxicology and Applied Pharmacology 280 (2014) 352–361incorporated is based on the pH-dependent chemistry of the chromate
species. The ﬁtted global parameters for the human data were then
K11, k1, R0,1, and f.
Initial concentrations. We also noted, however, that some of the time-
course data were not consistent with the nominal targeted initial Cr-
VI concentration. For example, the ﬁrst two data points (from repeat
experiments) for the set at pH = 4, dil = 2, and a target concentra-
tion of 2 mg/L had measured concentrations of 2.10 and 2.02 mg/L
at 0.5 min; i.e., greater than what should have been the initial con-
centration. With the initial reduction rate for this experiment being
very rapid, [Cr-VI]Total dropping to ~1.6 mg/L by 1.75 min, these
data appear consistent with an initial concentration somewhat
higher than 2 mg/L. Forcing the model to ﬁt these data with an as-
sumed initial concentration of 2 mg/L was found to create a bias in
the predicted reaction rate, tending to a rate slower than exhibited
by the data after those initial measurements. While less dramatic,
the data for pH = 4, dil = 10, with an initial target concentration
of 0.1 mg/L [Cr-VI]Total, also appeared more consistent with an initial
concentration slightly higher than the target. Other data sets ap-
peared consistent with initial concentrations lower than targeted.
We assumed that these apparent discrepanciesweremost likely due
to the difﬁculty of quickly mixing the reagents and then sampling the
reaction at such short times, and therefore thought it appropriate to
allow the modeled initial concentration for each experiment to vary
up to 10% from the targeted concentration. This allowed the model to
better capture the observed initial reaction rates (slope of concentration
vs. time data), which is the critical information contained in the data.
Since the human data included 9 experiments (combinations of pH,
dilution level, and initial chromate concentration), a total of 13 param-
eters were allowed to vary in ﬁtting those data: the 4 global parameters
(K11, k1, R0,1, and f) and the initial concentration for each of the 9 exper-
iments (constrained to bewithin 10% of the target concentration). The 9
data sets contained a total of 122 measurements, ranging from 10 to 17
per experiment, so there were just over 9 data points per ﬁtted
parameter.
Reducing agent pools. As stated in the introduction, the reductionmodel
used by Proctor et al. (2012) and Kirman et al. (2013) assumed a single
reducing agent (electron donor) pool, with the agent participating in a
binary reaction with Cr-VI. The reducing agent was assumed to have
an initial concentration, R0, which was adjusted to ﬁt the experimental
data along with the binary rate constant, keff. While the assumption of
a single reducing agent allowed for adequate model ﬁts to the lower
concentration data from the ex vivo rodent experiments, closer exami-
nation of the ﬁts to the high concentration (speciﬁcally, plotting the re-
sults with a linear y axis), showed that the amount of reduction
observed with higher initial Cr-VI concentrations was signiﬁcantly
under-predicted (Figs. 2–5). More speciﬁcally, while those data showed
an initial rapid reduction that was somewhat consistent with the single
pool model, after the ﬁrst 5–10 min, when the single-pool model pre-
dicts that reduction would cease due to depletion of the reducing
agent, the data show continued reduction, although at a slower rate.
Therefore we added terms to the model corresponding to additional
pools of reducing agent, but only so far as these resulted in signiﬁcant
improvement in model ﬁts.
While the rodent reduction experimentswere all conducted at a sin-
gle pH, we used the chromate speciation chemistry and relative contri-
butions determined from ﬁtting the human reduction data. Inclusion of
this pH-dependence is ultimately necessary for application of themodel
to reduction in vivo, since pH changes between sections of the rodent GI
tract (DeSesso and Jacobson, 2001; Kararli, 1995). In addition to the ini-
tial one-pool model, three other options were evaluated: a) two reduc-
ing agents (two-pool model) with corresponding deﬁned initial pool
sizes (concentration of reducing agent pre-reaction); b) three reducing
agents (three-pool model) with corresponding deﬁned pool sizes;c) three-pool model, but where the size of the third pool is sufﬁciently
large that it is not signiﬁcantly depleted for the experimental conditions
evaluated. For this third case an effective ﬁrst-order rate constant, kvsf,
replaces the product of a binary rate constant, kvs, and the concentration
of the pool, [Rvs]; i.e., kvsf, = kvs ∙ [Rvs]. This third option reduces the
number of ﬁtted parameters by one vs. the full three-pool model,
since the initial size of the third pool does not need to be estimated.
The reduction rate equations for the three options are:
a) two reducing agents: rred ¼ k f R f½  þ ks  Rs½ ð Þ  H2CrO4½  þð
HCrO4½  þ f  CrO42−
h i
Þ;
b) three reducing agents with ﬁnite third pool: rred ¼ k f R f½  þð ks 
Rs½  þ kvs  Rvs½ Þ  H2CrO4½  þ ½HCrO42−
 
;
c) three reducing agents with unknown or effectively unlimited third
pool: rred ¼ k f R f½  þ ks  Rs½  þ kvsfð Þ  H2CrO4½  þ HCrO4½  þð
f  ½CrO42−Þ:
Here the subscript “f” indicates a pool that is expected to react andbe
depleted quickly (fast), “s” indicates a pool that reacts and is depleted
(more) slowly, and “vs” one that reacts and is depleted very slowly.
Note that we are not suggesting that there is actually an inﬁnite reduc-
ing capacity in the 3rd pool for option (c), just that the concentrations of
Cr-VI used in the experiments are not sufﬁciently high to signiﬁcantly
deplete this third pool, hence the size of the pool cannot be estimated
using the data and it can be treated as unlimited in the concentration
range being analyzed.
Before describing our results, the number of data points used per
ﬁtted parameter should be evaluated to determine if the parameter es-
timation is sufﬁciently supported. The parameters that determine the
speciation of chromate, and the fractional contribution of CrO42−
(i.e., f) were determined using the human data as described above and
assumed to be identical for rodents, hence not further adjusted. Thus
in ﬁtting the options above (for mice or rats), (a) involved four kinetic
parameters (kf, R0,f, ks, and R0,s), (b) involved 6 kinetic parameters
(those for (a) plus kvs and R0,vs), and (c) involved 5 kinetic parameters
(those for (a) plus kvsf). For the mouse, data were available for 5 initial
chromate concentrations, which were also ﬁtted. Hence option (a),
(b), and (c) involved adjustment of 9, 11, and 10 parameters, respec-
tively. The 5 mouse data sets included a total of 84 measurements
(16–18 per set); hence the number of data points per parameter was
9.3, 7.6, and 8.4 for (a), (b), and (c), respectively.
For the rat there were only 3 chromate concentration data sets, so in
evaluating among the options a total of 7, 9, and 8 parameters were ad-
justed for (a), (b), and (c), respectively, with a total of 49 data points.
Hence option (b) only had 5.4 data points per parameter. However,
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estimated from modeling the mouse data, reducing the number ﬁtted
for the rat option (c) to 6 parameters, thus with just over 8 data points
per parameter. In combination, applying option (c) to both the mouse
and rat data sets used 133 data points and 16 parameters (8 being
constrained), or 8.3 points per parameter.
Results
Parameter optimizationswere independently performed for rodents
applying each of the three options above using the Nelder–Mead algo-
rithm in acslXtreme. Both option (b) and option (c) provided signiﬁcant
improvement over option (a). However, option (b) did not produce suf-
ﬁciently superior results over option (c), and parameters for the third
reaction (kvs and R0,vs) were not uniquely identiﬁable. Only the single
product term could be optimized (essentially kvsf). Therefore, option
(c) was determined to be the best model structure for rodents. As indi-
cated above, we interpret option (c) as indicating that the size of the
third pool is simply much larger than the concentration range used in
these experiments, so its concentration cannot be estimated with rea-
sonable accuracy using model form (b).
For the rat it was found that therewas not a signiﬁcant improvement
in ﬁt when kf and ks were varied vs. ﬁxed at the values estimated for the
mouse (results with these two ﬁtted separately for the rat not shown).
Hence their values listed in Table 1 are identical for mice and rats.
Fig. 2 illustrates the differences in model predictions between the
original assumption (one reducing agent), and the revised two- and
three-reducing agent schemes for the rat. Fig. 3 illustrates the original
and revised (three-reducing agent) model results for the mouse. For
the human, a single reducing agent pool assumption was adequate,
since the addition of two or three pools did not sufﬁciently improve
themodel, and the additional parameterswere non-identiﬁable. Howev-
er, the revised,moremechanisticmodel structure and re-optimization of
parameters resulted in signiﬁcantly improved model ﬁts over the origi-
nal model. Results for the human are presented in Figs. 4–5. The ﬁnal
ex-vivo kinetic parameters for all species are contained in Table 1.
Examining the kinetic data for rats and mice shown in Figs. 2 and 3,
one can see that at the highest initial Cr-VI concentrations there is sig-
niﬁcant reduction between 20 and 60 min, with no clear evidence that
the reducing capacity has been depleted or saturated. The data and
the revised model are consistent with continued reduction beyond
60 min and clearly inconsistent with the predictions of the original,
one-pool model. This inconsistency was not evident in the publication
of Proctor et al. (2012) because of the compressed, log-y axis used in
their plots. Depletion of 100% reducing capacity in rodents at high con-
centration is only estimated by the original single reducing agentmodel,
and could be shown at later time points or with yet higher Cr-VITable 1
Final kinetic parameters for Cr-VI reduction in gastric juice of rats and mice (3-pools) and
humans (1-pool).
Symbol Deﬁnition (units) Value
Species-independent parameters
K11 Equilibrium constant (M−1) 1080
K22 Equilibrium constant (M−1) 132
K21 Equilibrium constant (M−1) 13.2
K32 Equilibrium constant (M−1) 15.2
f Fractional reactivity of CrO42− (no units) 0.0025
Rat Mouse Human
Species-speciﬁc parameters
kf or k1 Fast binary rate constant (L/mg-min) 2.4a 2.4 0.62
ks Slow binary rate constant (L/mg-min) 0.15a 0.15 –
kvs Very slow ﬁrst-order constant (1/min) 0.058 0.044 –
R0,f or R0,1 Fast reducing agent pool size (mg/L) 4.1 2.9 10
R0,s Slow reducing agent pool size (mg/L) 18 31 –
a kf and ks for the rat where ﬁxed at the values estimated for the mouse.concentrations. But based on these on these results it appears that use
of the original reductionmodelmay result in over-estimation of internal
doses of Cr-VI when incorporated into a rodent physiologically-based
pharmacokinetic model, because it under-estimates reduction in the
20–60 min time-frame.
Similar to the rodent, the original reaction scheme predicts reducing
agent depletion at high concentration in the human (Fig. 4). Despite
being limited to only a single reducing agent pool, the revised model
more closely reproduces the data, and does not predict a complete de-
pletion of reducing agent in the Cr-VI concentration range used. It
should be noted, though, that the highest Cr-VI concentration used in
the human ex-vivo experiments was 2mg/L in a gastric juice sample di-
luted only 2-fold, while the rat experiments were conducted up to
16 mg/L and the mouse up to 42 mg/L, in gastric juice samples diluted
10-fold. Hence the rodent data were sufﬁcient to show multiphase de-
pletion curves consistent with multiple pools of reducing agent, while
the human data were not. The revised ex-vivomodel also gives amech-
anistic understanding of the pH-dependence of Cr-VI reduction. Al-
though several parameters had to be adjusted to ﬁt the human ex-
vivo data, it captures the pH-dependence in the experimental data
much more accurately. If incorporated into a PBPK model (work ongo-
ing), the revised reaction scheme should provide an improved analysis
of the effect of stomach pH variations on Cr-VI reduction.
It has been previously suggested that at high Cr-VI concentrations in
rodent gastric juice, the reducing capacity is overwhelmed or depleted,
thereby having signiﬁcant implications for the interpretation of toxico-
logical data in rodents (Thompson et al., 2013). For example, Table 2
(adapted from Proctor et al. (2012)) illustrates a manner in which
species-differences in Cr-VI reduction capacity may be interpreted. If
one examines the reducing capacity of only one of the kinetic reactions,
it may be concluded that mice are more susceptible than rats, since
when compared per drinking event, rats have about 50% higher reduc-
ing capacity. For example, by the original model at 21 mg/L a mouse is
predicted to consume 130% of its reducing capacity per drinking event
while the rat is predicted to consume 94% of its capacity. Likewise for
our revisedmodel the reducing capacity of the “fast” pool in the rat, rel-
ative to a drinking event, is predicted to be about twice that of the “fast”
pool in the mouse. However if both the “fast” and “slow” reducing ca-
pacities estimated using the revised model are added together
(neglecting the impact of the third “very slow” reaction with undeter-
mined capacity), the difference in susceptibility becomes negligible.
The revisedmodel suggests that under the complexphysiological condi-
tions of the stomach, a combination of slow, fast, and very slow reduc-
tion reactions will be simultaneously competing with each other and
the gastric emptying process. However the reducing capacities are just
one of many factors impacting the reduction and systemic uptake of
Cr-VI.
Discussion
The work presented here is an extension of the model by Proctor
et al. (2012) and Kirman et al. (2013), and incorporates mechanistic re-
action schemes to describe ex-vivo Cr-VI reduction kinetics in humans
and rodents. The model was chosen to balance parsimony with mecha-
nistic complexity. The revised Cr-VI reduction model is more complex
than the previous models in two ways: the assumption of multiple
reducing agent pools and a more elaborate description of pH-
dependence. Predicting dosimetry under long-term exposure condi-
tions is desirable, so the reduction model should accurately predict the
experimental data beyond the ﬁrst 20 min, at least to the 60 min
time-point for which data are available, across the tested concentration
range. For comparison, the NTP bioassay exposed mice and rats to
5–180mg/L Cr-VI equivalents (NTP, 2008). Ingestedwaterwill be dilut-
ed into the entire gastric contents, so the relevant concentration will be
less than in the drinkingwater, making the lower end of the concentra-
tion range evaluated here most important. The analysis of which dose
Table 2
Comparison of mouse and rat Cr6 stomach loading and reducing capacity (adapted from Proctor et al. (2012)).
Cr6 DW
(mg/L)
Water intake
per event (L)
Cr6 intake per
event (mg)
Reducing capacity
(mg/mL)
Stomach contents
(mL)
Total reducing
equiv. (mg)
Cr6 intake per event as % of reducing
capacity
Orig. Fast Fast + slow
Mouse
0.1 0.0002 0.00002 0.0166 (original)a 0.2 0.0033 (original) 0.6 3.4 0.3
0.00058 (fast)
1.4 0.00028 0.0029
(fast)b
0.00678
(fast + slow)
8.5 48.3 4.1
5 0.001 0.0339
(fast + slow)c
30 172 15
21 0.0042 130 724 62
60 0.012 360 2069 177
180 0.036 1100 6207 531
Rat
0.1 0.0007 0.00007 0.0157 (original)a 1 0.0157
(original)
0.0041
0.4 1.7 0.3
1.4 0.00098 0.0041
(fast)b
(fast)
0.0221
(fast + slow)
6.2 24 4.4
5 0.0035 22 85 16
21 0.0147 0.0221
(fast + slow)c
94 360 67
60 0.042 270 1024 190
180 0.1274 810 3107 577
a Original published value.
b R0f from Table 1.
c The sum of R0f and R0s from Table 1.
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estimate of that capacity, which is provided by the higher concentration
ex vivo data. For humans the relevant range is much lower. The highest
level reported in drinking water was 0.097 mg/L (as of March 3, 2014),
with most samples falling below 0.003 mg/L (3 ppb) (USEPA, 2014).
While the concentration range examined by Kirman et al. (2013) and
re-evaluated here is orders of magnitude higher, the changes proposed
for the human reduction model were not in the number of reducing
agent pools (which would only be important at higher concentrations),
but in the pH-dependence.
In both Figs. 2 and 3 the improvement in model ﬁt to the total data
set is clear. A slightly simpler variation considered used only 2 pools of
reducing agent, but as shown in the 14 ppm data set in Fig. 2, the addi-
tion of a third pool (using a single ﬁrst-order rate constant) provides a
signiﬁcant additional improvement at the higher concentration. Similar
improvements occur at 15 and 40 ppm in the mouse gastric reduction
(data in Fig. 3, but 2-pool model not shown). On the other hand intro-
ducing two more parameters, speciﬁcally a binary constant and reduc-
tion capacity for the third pool, provided a negligible improvement
over the results shown,with large uncertainty in the third pool capacity.
That multiple pools of reducing agents (electron donors) exist in gastric
juice, including ascorbate, NADH, and glutathione, was noted by Proctor
et al. (2012). Thus the revised model is also consistent with the bio-
chemical constituents in gastric juice.
A mathematical model can be overly complicated if it contains pa-
rameters that are not identiﬁable given the existing data, especially if
this lack of identiﬁability leads to uncertainty in model predictions.
Therefore a certain level of parsimony is desirable. But parsimony
alone would lead one to choose a classical pharmacokinetic (PK)
model over a physiologically-based pharmacokinetic (PBPK) model,
since the former is clearly simpler and has fewer parameters. The
counterbalancing principle that has led to the use of PBPK models in
risk assessment is mechanistic plausibility, which is expected to in-
crease a model's reliability when used to predict data outside of the ob-
served range and conditions. PBPKmodels do not introducemanymore
parameters in the absence of additional data. They make use of data on
tissue volumes, blood ﬂows, and respiration rate, in addition to
chemical-speciﬁc data. While the PBPK model structure is moreelaborate than a classical PK model, together with the physiological pa-
rameters that are generally not ﬁtted during model calibration, the
resulting PBPK model predictions are much less sensitive to the ﬁtted
chemical-speciﬁc parameters than a classical PK model. Hence the un-
certainty due to its ﬁtting to a limited data set is constrained. For exam-
ple, hepatic metabolism in a PBPK model is limited by blood-ﬂow and,
ultimately, inhalation rate for inhaled gases. Therefore, the impact of
uncertainty in the Vmax for hepatic metabolism is minimal for large
values of Vmax.
Likewisewhen there are data that amodel does notﬁt and these dis-
crepancies are indicative of systematic errors in a model – i.e., trends
with experimental conditions such as time or concentration not cap-
tured by a model – and elaborations of the model improve its ability
to capture these trends, then such elaborations can improve a model's
predictive reliability. If a more complex model structure is obtained
from mechanistic knowledge of speciﬁc processes involved, and if that
knowledge derives from other experimental data, then added model
complexity can improve predictability (rather than increasing uncer-
tainty). This is particularly true if underlying parameter values are de-
rived from independent, supporting experimental data. For the revised
reductionmodel, three of the four equilibrium constants that determine
the speciation (for reactions 1–4) were identiﬁed independently from
other experimental data and not adjusted here. The revised model
now accurately captures the variation in reduction rate with pH as
shown in Figs. 4 and 5. The rate and extent of Cr-VI reduction predicted
for humans vs. rodents will directly impact the estimated cancer risk in
humans. Therefore we sought to improve the ability of the gastric-juice
reduction models to ﬁt the reduction data of Proctor et al. (2012) and
Kirman et al. (2013) in order to more accurately estimate the relative
dosimetry and hence risk in humans. The impact of these changes can
only be evaluated in the context of a PBPK model which integrates gas-
tric reduction in various GI compartments with rates of ingestion, co-
factor replenishment, Cr absorption, etc. Those results will be described
in a subsequent publication. However, independent of the extent to
which use of the revised reduction model might quantitatively change
the exposure–internal-dose relationship, that the revised model better
describes the overall data set with minimal additional parameters
should improve the level of conﬁdence in those predictions.
361P.M. Schlosser, A.F. Sasso / Toxicology and Applied Pharmacology 280 (2014) 352–361The ex vivo reductionmodel described here can be incorporated into
1) a gastrointestinal tract model and, subsequently 2) a whole-body
PBPKmodel (Fig. 1). While preliminary results regarding species differ-
ences were obtained using only the ex vivo reduction kinetics (Table 1),
a more complete analysis can only be done by taking into account gas-
tric dynamics and differences in systemic absorption. Gastric and
whole-body PBPK models deﬁning the processes speciﬁc to Cr(VI)
were previously described by (Kirman et al., 2013; Kirman et al.,
2012). Updating these models to incorporate the revised reduction ki-
netics is the subject of ongoing work.Disclaimer
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